IN2015MN00002A - - Google Patents
Info
- Publication number
- IN2015MN00002A IN2015MN00002A IN2MUN2015A IN2015MN00002A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A IN 2MUN2015 A IN2MUN2015 A IN 2MUN2015A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A
- Authority
- IN
- India
- Prior art keywords
- stereoisomer
- amenable
- disorders
- inhibiting
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (pl) | 2012-07-09 | 2013-07-09 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN762KO2012 | 2012-07-09 | ||
| IN2MUN2015 IN2015MN00002A (pl) | 2012-07-09 | 2013-07-09 | |
| PCT/IB2013/055618 WO2014009872A1 (en) | 2012-07-09 | 2013-07-09 | Tetrahydroquinazolinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00002A true IN2015MN00002A (pl) | 2015-10-16 |
Family
ID=48906465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (pl) | 2012-07-09 | 2013-07-09 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9359367B2 (pl) |
| EP (1) | EP2870140B8 (pl) |
| AU (1) | AU2013288265B2 (pl) |
| CA (1) | CA2877826C (pl) |
| ES (1) | ES2595240T3 (pl) |
| IN (1) | IN2015MN00002A (pl) |
| WO (1) | WO2014009872A1 (pl) |
| ZA (1) | ZA201409497B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3130592T3 (da) * | 2014-04-10 | 2019-11-04 | Hubei Bio Pharmaceutical Industrial Tech Institute Inc | ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER |
| WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| BR112018002465A2 (pt) * | 2015-08-17 | 2018-09-18 | Lupin Ltd | derivados de heteroarila como inibidores de parp |
| CN108822115B (zh) * | 2017-04-21 | 2022-08-12 | 上海迪诺医药科技有限公司 | 一种抑制parp活性的化合物的制备方法及其中间体 |
| HRP20230183T1 (hr) * | 2017-12-21 | 2023-05-12 | Ribon Therapeutics Inc. | Kinazolinoni kao inhibitori parp14 |
| CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
| CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| BE503170A (pl) | 1975-09-02 | |||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | History (Aza) Naftalensultam, their preparation and preparations containing them |
| DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
| DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
| US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
| AU2001249262A1 (en) | 2000-03-20 | 2001-10-03 | Sepracor, Inc. | Therapeutic compounds for the treatment of asthma and allergy, and methods of use thereof |
| ES2211738T3 (es) | 2000-08-03 | 2004-07-16 | Pfizer Products Inc. | Derivados de diazabiciclooctano y sus usos terapeuticos. |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| WO2003006423A1 (en) | 2001-07-11 | 2003-01-23 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| JP2005536553A (ja) | 2002-08-21 | 2005-12-02 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6－氯－4－羟基－2－甲基－2H－噻吩并（2，3－e）－1，2－噻嗪－1，1－二氧化物－3－羧酸酯的合成方法 |
| AU2004265022A1 (en) | 2003-08-18 | 2005-02-24 | H.Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| DK1684736T3 (da) | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| JP4912145B2 (ja) | 2004-02-26 | 2012-04-11 | あすか製薬株式会社 | ピリミジン誘導体 |
| US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
| US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| KR20070008709A (ko) | 2004-04-30 | 2007-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 이종환식 아미드 화합물 및 이의 ｍｍｐ-13 저해제로서의용도 |
| AU2005259188B2 (en) | 2004-06-30 | 2011-03-31 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as PARP inhibitors |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| JPWO2006051851A1 (ja) | 2004-11-10 | 2008-05-29 | わかもと製薬株式会社 | ２，３，４，５−テトラヒドロ−１ｈ−１，５−ベンゾジアゼピン誘導体、及び、医薬組成物 |
| BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
| ES2365747T3 (es) | 2005-03-23 | 2011-10-10 | Actelion Pharmaceuticals Ltd. | Derivados de benzo[c]tiofeno hidrogenados como inmunomoduladores. |
| JPWO2006137510A1 (ja) | 2005-06-24 | 2009-01-22 | 小野薬品工業株式会社 | 脳血管障害時における出血低減剤 |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| US20070032502A1 (en) | 2005-07-15 | 2007-02-08 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| CA2630900A1 (en) | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Use of parp-1 inhibitors |
| CN101360738A (zh) | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| WO2007127175A2 (en) | 2006-04-26 | 2007-11-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| WO2008080824A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Aromatic sulfonated ketals |
| JPWO2009038064A1 (ja) | 2007-09-19 | 2011-01-06 | 株式会社医薬分子設計研究所 | Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体 |
| JP2009096804A (ja) | 2007-09-26 | 2009-05-07 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
| WO2009041566A1 (ja) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
| WO2009114459A2 (en) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| SG171956A1 (en) | 2008-12-05 | 2011-07-28 | Hoffmann La Roche | Pyrrolopyrazinyl urea kinase inhibitors |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| DK2550258T3 (en) | 2010-03-25 | 2015-12-07 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| AU2011298423B2 (en) | 2010-09-03 | 2015-11-05 | Bayer Intellectual Property Gmbh | Substituted fused pyrimidinones and dihydropyrimidinones |
-
2013
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/en not_active Not-in-force
- 2013-07-09 CA CA2877826A patent/CA2877826C/en not_active Expired - Fee Related
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/en active Application Filing
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2877826C (en) | 2016-08-16 |
| ES2595240T3 (es) | 2016-12-28 |
| AU2013288265A1 (en) | 2015-01-29 |
| EP2870140B1 (en) | 2016-07-27 |
| EP2870140A1 (en) | 2015-05-13 |
| US9359367B2 (en) | 2016-06-07 |
| ZA201409497B (en) | 2015-12-23 |
| US20150152118A1 (en) | 2015-06-04 |
| WO2014009872A1 (en) | 2014-01-16 |
| AU2013288265B2 (en) | 2017-04-06 |
| CA2877826A1 (en) | 2014-01-16 |
| EP2870140B8 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| IN2015MN00002A (pl) | ||
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2023001876A (es) | Derivados de rapamicina. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| MX363605B (es) | Compuestos bicíclicos fusionados de azaindazol o diazaindazol para usarse en el tratamiento o prevención del dolor. | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| CA2881554C (en) | Methods for inhibiting fascin | |
| MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| NZ726695A (en) | Gls1 inhibitors for treating disease | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. |